Shi Kejian, Fu Wenjiao, Farhadi Sabet Zeinab, Ye Jinmin, Liang Shijian, Liu Tao, Liu Qiaolin, Guo Mengyu, You Min, Wu Junguang, Bai Ru, Liu Ying, Hu Bin, Cui Xuejing, Li Jiayang, Chen Chunying
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, New Cornerstone Science Laboratory, National Center for Nanoscience and Technology of China, Beijing 100190, People's Republic of China.
Sino-Danish College, Sino-Danish Center for Education and Research, University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
ACS Nano. 2024 Dec 3;18(48):33042-33057. doi: 10.1021/acsnano.4c07603. Epub 2024 Oct 23.
Hypoxia, a common occurrence within solid tumors, can stimulate the dissemination of deceptive tumor exosomes, which function as communicative bridges and orchestrate the recruitment of various supportive cell types for enhanced tumor adaptability in a tumor immune microenvironment. Current nanotechnology provides us intelligent strategies to combat the hypoxic tumor microenvironment. However, once exposed to external stimuli, such as chemotherapy, tumor cells simultaneously release malignant signals to develop tumor migration and immunosuppression, posing challenges to clinical practice. Taking advantage of the membrane-targeting therapeutic strategy, the application of a self-assembled short peptide (PepABS-y), affording hydrogels on tumor cell surfaces, can block exosome dissemination with fiber-like nanostructures and effectively limit the systemic adverse effects of traditional therapeutics. Moreover, PepABS-y can attenuate the hypoxic tumor microenvironment by carrying an inhibitor of the hypoxic tumor-overexpressed CA IX enzyme, where hypoxia is also a crucial regulator to induce tumor exosomes and mediate intercellular communications within the immune system. Herein, its application on jamming exosome communications can target the T cell-related signaling pathway by regulating microRNAs in exosome cargoes and ultimately enhances CD8 T cell infiltration and alleviates inflammatory monocytes at metastasis sites. Collectively, with the capability of blocking exosome dissemination, PepABS-y can be applied as a promising tumor membrane-targeting therapeutic tool to counter tumor adaption within an immune microenvironment and further advance traditional chemotherapy.
缺氧是实体瘤中常见的现象,它可以刺激具有欺骗性的肿瘤外泌体的传播,这些外泌体充当通讯桥梁,并协调各种支持性细胞类型的募集,以增强肿瘤在肿瘤免疫微环境中的适应性。当前的纳米技术为我们提供了对抗缺氧肿瘤微环境的智能策略。然而,一旦暴露于外部刺激,如化疗,肿瘤细胞会同时释放恶性信号,从而导致肿瘤迁移和免疫抑制,给临床实践带来挑战。利用膜靶向治疗策略,应用一种在肿瘤细胞表面形成水凝胶的自组装短肽(PepABS-y),可以通过纤维状纳米结构阻断外泌体的传播,并有效限制传统疗法的全身不良反应。此外,PepABS-y可以携带缺氧肿瘤中过表达的碳酸酐酶IX(CA IX)酶的抑制剂来减轻缺氧肿瘤微环境,其中缺氧也是诱导肿瘤外泌体和介导免疫系统内细胞间通讯的关键调节因子。在此,其在干扰外泌体通讯方面的应用可以通过调节外泌体货物中的微小RNA来靶向T细胞相关信号通路,并最终增强CD8 T细胞浸润,减轻转移部位的炎性单核细胞。总的来说,凭借阻断外泌体传播的能力,PepABS-y可以作为一种有前景的肿瘤膜靶向治疗工具,以对抗免疫微环境中的肿瘤适应性,并进一步推进传统化疗。